(Total Views: 737)
Posted On: 09/11/2021 1:36:44 PM
Post# of 72440
Pre-pandemic IPIX PRs are an excellent reminder of the enormous potential and market opportunities for Brilacidin. IPIX has been rightfully focused on B-CV19 the past 19 months but there are many various market opportunities that can be and will be targeted once funding is no longer a limiting factor. Long term IPIX investors were committed to their IPIX investment in most cases many years before Brilacidin was being considered as an antiviral therapeutic. Our patience will soon be rewarded IMO as phase 2 B-CV19 results will advance Brilacidin as the gold standard for CV19 and as a Broad Spectrum antiviral solution.
The PR from 1/2/19 is a window to the vast areas of need and opportunities for Brilacidin. A little over a year later on 2/13/20, IPIX announced top line results of the phase 1 to confirm that Brilacidin could be successfully delivered orally to specific targeted areas for IBD treatment. Only 5 days later on 2/18/20, IPIX issued their first of many PRs for the investigation of Brilacidin as a possible weapon against CV19. I personally believe that this redirection in focus will prove to save millions of lives and that the funding and revenue from B-CV19 will advance the entire Brilacidin platform to treat a multitude of various diseases.
==========================================================
From IPIX PR 1/2/19
The “Issue Notification” of the patent (Projected U.S. Patent Number 10166232) covers Brilacidin in the form of a pharmaceutical composition containing water. The pharmaceutical composition can also contain Tris-buffered saline. The patent covers Brilacidin in combination with additional medicaments, such as: an antibiotic, an anti-inflammatory agent, an anesthetic agent, an anti-allergic agent, an acetylcholine blocking agent, an adrenergic agonist, a beta-adrenergic blocking agent, an anti-glaucoma agent and an anti-hypertensive agent.
The new patent builds on the “Notice of Allowance” directed to Brilacidin, including oral, buccal, and sublingual pharmaceutical compositions of Brilacidin.
The PR from 1/2/19 is a window to the vast areas of need and opportunities for Brilacidin. A little over a year later on 2/13/20, IPIX announced top line results of the phase 1 to confirm that Brilacidin could be successfully delivered orally to specific targeted areas for IBD treatment. Only 5 days later on 2/18/20, IPIX issued their first of many PRs for the investigation of Brilacidin as a possible weapon against CV19. I personally believe that this redirection in focus will prove to save millions of lives and that the funding and revenue from B-CV19 will advance the entire Brilacidin platform to treat a multitude of various diseases.
==========================================================
From IPIX PR 1/2/19
The “Issue Notification” of the patent (Projected U.S. Patent Number 10166232) covers Brilacidin in the form of a pharmaceutical composition containing water. The pharmaceutical composition can also contain Tris-buffered saline. The patent covers Brilacidin in combination with additional medicaments, such as: an antibiotic, an anti-inflammatory agent, an anesthetic agent, an anti-allergic agent, an acetylcholine blocking agent, an adrenergic agonist, a beta-adrenergic blocking agent, an anti-glaucoma agent and an anti-hypertensive agent.
The new patent builds on the “Notice of Allowance” directed to Brilacidin, including oral, buccal, and sublingual pharmaceutical compositions of Brilacidin.
(10)
(1)Scroll down for more posts ▼
